COMMUNIQUÉS West-GlobeNewswire
-
Leadership Team Expansion to Support the Need for Healthier Employees
28/04/2026 -
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
28/04/2026 -
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
28/04/2026 -
Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer
28/04/2026 -
Holivita Launches a New Platform, Offering a Human-Centric Blueprint for Health Through AI and Your DNA
28/04/2026 -
Dr. Björn Zoëga: Scaling Integrated Digital Systems Will Define the Future of Healthcare
28/04/2026 -
Yinuo Chen, founder of three major Fertility centers—Tulip, ONELIFE, and Sino—was invited to participate in the Shanghai Medical Exhibition
28/04/2026 -
Reacta Healthcare Announces Expansion into Asia-Pacific and Appoints Professor Gary Wing-Kin Wong to Advisory Board
28/04/2026 -
Clariane has launched a proposed offering of €230 million of additional senior notes to refinance its hybrid green perpetual bonds
28/04/2026 -
Transactions in connection with share buy-back program
28/04/2026 -
KFSH Awards Innovation Challenge Winners at C3 Davos of Healthcare™ Silicon Valley Summit
28/04/2026 -
Clariane annonce l’offre de 230 millions d’euros d’obligations senior additionnelles en vue de refinancer ses obligations hybrides vertes perpetuelles
28/04/2026 -
Dr. Petros Kotsidis: KFSH Positions AI as a Scalable Model for Real-World Healthcare Innovation
28/04/2026 -
Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year
28/04/2026 -
Castle Rock Hormone Health Announces National Franchise Launch with Franchise Sidekick Amid Growing Demand for Longevity Medicine
28/04/2026 -
Bioxodes to present final Phase 2a trial results confirming breakthrough potential of BIOX-101 for intracerebral hemorrhage in poster at ESOC 2026
28/04/2026 -
Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025
28/04/2026 -
CORE Soft Tissue Therapy Reports Full Booking Capacity in First Year as Referral Growth Supports South London Expansion
28/04/2026 -
Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy
28/04/2026
Pages